NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V)
(“
NurExone” or the “
Company”)
announces that it intends to complete a non-brokered private
placement (the “
Private Placement”) of a minimum
of 2,727,272 units (“
Units”) and a maximum of
5,090,909 Units at a price of CAD$0.275 per Unit for minimum gross
proceeds of $750,000 and maximum gross proceeds of $1,400,000. Each
Unit will consist of (i) one common share in the capital of the
Company (each, a “
Common Share”); (ii) one-half of
one class A Common Share purchase warrant (each whole class A
Common Share purchase warrant, a “
Class A
Warrant”); and (iii) one-half of one class B Common Share
warrant (each whole class B Common Share warrant, a “
Class
B Warrant” and collectively each whole Class A Warrant and
each whole Class B Warrant, a “
Warrant”). Each
Class A Warrant will entitle the holder thereof to purchase one
Common Share at a price of $0.34 per Common Share for a period of
24 months from the closing of the Private Placement and each whole
Class B Warrant will entitle the holder thereof to purchase one
Common Share at a price of $0.48 per Common Share for a period of
36 months from the closing of the Private Placement.
The Warrants will be subject to accelerated
expiration whereby if the daily volume weighted average trading
price of the Common Shares on the TSX Venture Exchange
(“TSXV”) for any period of 20 consecutive trading
days equals or exceeds $0.69 in respect of the Class A Warrants or
$0.83 in respect of the Class B Warrants, the Company may, upon
providing written notice to the holders of the Class A Warrants or
Class B Warrants, as applicable (the “Acceleration
Notice”), accelerate the expiry date of the respective
Class A Warrants or Class B Warrants to the date that is 30 days
following the date of the Acceleration Notice. If the Warrants are
not exercised by the applicable accelerated expiry dates, the
Warrants will expire and be of no further force or effect.
The Company intends to use the proceeds of the
Private Placement for working capital purposes. The Private
Placement is subject to the approval of the TSXV, and all
securities issued thereunder will be subject to a statutory hold
period of four months and one day from the closing of the Private
Placement. Finder’s fees may be payable in connection with the
Private Placement, all in accordance with the policies of the TSXV
and applicable securities laws.
This news release does not constitute an offer
to sell or a solicitation of an offer to buy any of the securities
described in this news release in the United States. Such
securities have not been, and will not be, registered under the
United States Securities Act of 1933, as amended (the “U.S.
Securities Act”), or any state securities laws, and,
accordingly, may not be offered or sold within the United States,
or to or for the account or benefit of persons in the United States
or “U.S. Persons”, as such term is defined in Regulation S
promulgated under the U.S. Securities Act, unless registered under
the U.S. Securities Act and applicable state securities laws or
pursuant to an exemption from such registration requirements.
About NurExone
Biologic Inc.
NurExone Biologic Inc. is a TSX Venture
Exchange-listed pharmaceutical company that is developing a
platform for biologically-guided ExoTherapy to be delivered,
non-invasively, to patients who suffered traumatic spinal cord
injuries.
ExoTherapy, utilizing extracellular vesicles or
exosomes, was conceptually demonstrated in animal studies at the
Technion, Israel Institute of Technology. NurExone is translating
the treatment to humans, and the Company holds an exclusive
worldwide license from the Technion and Tel Aviv University for the
development and commercialization of the technology.
For additional information, please visit
www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook,
or YouTube.
For further
information, please
contact:
Dr. Lior ShaltielChief Executive Officer and
Director Phone: +972-52-4803034
Inbar Paz-BenayounAdv. Head of Communications
and Investor Relations Phone: +972-52-3966695Email:
info@nurexone.com
Investor Relations (Canada) Phone: +1
905-347-5569Email: IR@nurexone.com
FORWARD-LOOKING
STATEMENTS
This press release contains “forward-looking
statements” that reflect the Company’s current expectations and
projections about its future development. When used in this press
release, forward-looking statements can be identified by the use of
words such as “may,” or by such words as “will,” “intend,”
“believe,” “estimate,” “consider,” “expect,” “anticipate,” and
“objective” and similar expressions or variations of such words.
Forward-looking statements are, by their nature, not guarantees of
the Company’s future operational or financial performance and are
subject to risks and uncertainties and other factors that could
cause the Company’s actual results, performance, prospects, or
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements. No representation or
warranty is intended with respect to anticipated future results, or
that estimates, or projections will be sustained.
Forward-looking statements are necessarily based
on estimates and assumptions made by us in light of our experience
and perception of historical trends, current conditions, and
expected future developments, as well as the factors we believe are
appropriate. Forward-looking statements in this press release
include, but are not limited to, statements relating to the Private
Placement, the proposed proceeds under the Private Placement, and
the approval requirements of the Private Placement.
In developing the forward-looking statements in
this press release, we have applied several material assumptions,
including our ability to attract investors on the terms under the
Private Placement; the general business and economic conditions of
the industries and countries in which we operate; and the market
conditions.
Many risks, uncertainties, and other factors
could cause the actual results of the Company to differ materially
from the results, performance, achievements, or developments
expressed or implied by such forward-looking statements. These
risks, uncertainties, and other factors include, but are not
limited to, the following: those risk factors identified under the
heading “Risk Factors” pages 29 to 36 of the Company’s Annual
Information Form dated March 30, 2023, a copy of which is available
under the Company’s SEDAR+ profile at www.sedarplus.ca, and other
similar factors that may cause the actual results, performance or
achievements to differ materially from those expressed or implied
in these forward-looking statements. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of the press release or as of the date
otherwise specifically indicated herein. Due to risks and
uncertainties, events may differ materially from current
expectations. The Company disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise, except as
required pursuant to applicable securities law.
All forward-looking statements contained in the
press release are expressly qualified in their entirety by this
cautionary statement. Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Nurexone Biologic (TSXV:NRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Nurexone Biologic (TSXV:NRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024